Amgen (AMGN) Total Non-Current Liabilities (2009 - 2026)
Amgen (AMGN) posted quarterly Total Non-Current Liabilities of $90.1 billion for Q1 2026, up 3.42% year-over-year from $87.2 billion in Q1 2025, and up 2.19% quarter-over-quarter from $88.2 billion in Q4 2025.
Amgen (AMGN) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Amgen's Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $90.1 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 3.42% year-over-year to $90.1 billion; the TTM figure through Mar 2026 stood at $90.1 billion (up 3.42% YoY), while the FY2025 annual figure was $88.2 billion, down 1.43% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $90.1 billion, up from $88.2 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $92.9 billion in Q1 2024, with the low at $53.7 billion in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $88.4 billion (2023), against an average of $82.2 billion.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities fell 6.47% in 2022, then jumped 67.66% in 2023.
- Amgen's Total Non-Current Liabilities stood at $64.9 billion in 2022, then soared by 42.59% to $92.5 billion in 2023, then dropped by 3.23% to $89.5 billion in 2024, then decreased by 1.43% to $88.2 billion in 2025, then increased by 2.19% to $90.1 billion in 2026.
- Business Quant data shows AMGN's Total Non-Current Liabilities at $90.1 billion in Q1 2026, $88.2 billion in Q4 2025, and $87.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 32.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.80 Bn |
| Mar 31, 2026 | 90.14 Bn |
| Dec 31, 2025 | 88.21 Bn |
| Sep 30, 2025 | 87.53 Bn |
| Jun 30, 2025 | 85.56 Bn |
| Mar 31, 2025 | 87.16 Bn |
| Dec 31, 2024 | 89.49 Bn |
| Sep 30, 2024 | 88.60 Bn |
| Jun 30, 2024 | 90.80 Bn |
| Mar 31, 2024 | 92.88 Bn |
| Dec 31, 2023 | 92.47 Bn |
| Sep 30, 2023 | 90.44 Bn |
| Jun 30, 2023 | 90.02 Bn |
| Mar 31, 2023 | 88.45 Bn |
| Dec 31, 2022 | 64.85 Bn |
| Sep 30, 2022 | 60.83 Bn |
| Jun 30, 2022 | 53.69 Bn |
| Mar 31, 2022 | 56.46 Bn |
| Dec 31, 2021 | 60.82 Bn |
| Sep 30, 2021 | 62.83 Bn |